General Prognostics announces start of first-ever study of Bloodless Blood Tests in heart failure monitoring together with University of Kansas Medical Center

GPx’s pioneering, potentially life-saving Bloodless Blood Tests technology identifies worsening trends before a patient becomes symptomatic, allowing the physician to optimize therapy, stabilize the patient’s condition, and potentially prevent a costly and dangerous hospital readmission. Bloodless Blood Tests leverage AI to calibrate digital biomarkers with blood biomarkers, delivering clinically actionable information about HF patient status on a timely basis. Current HF remote patient monitoring options have not proven effective ways to broadly reduce HF hospitalization rates due to inaccuracy, user burden, and cost. Providing heart failure clinicians with more actionable information may help keep patients stable on optimal medications and avoid hospitalizations.
 
Study takes place at the University of Kansas Medical Center, under the direction of the study’s Principal Investigator, Andrew J. Sauer, M.D., Associate Professor of Cardiovascular Medicine at the University of Kansas Medical Center. “The widespread use of wearables and GPx’s innovative pairing with blood biomarkers may be the start of non-invasive early warning systems on-par with currently available implanted solutions to improve HF care. We are pleased to participate in this study because it is the first in the world to evaluate a hybrid blood-digital remote monitoring paradigm,” said Dr. Sauer. 
 
The aim of the study is to evaluate GPx’s heart failure solution – CardioID^SM – among individuals with advanced heart failure, who are remotely monitored with an mSafety™ wearable device from Sony Network Communications Europe and an at-home blood test. The results of the study will gauge patient compliance and satisfaction ahead of a larger follow-on study at multiple hospitals that will evaluate the clinical impact of the monitoring platform. 
 
The novel approach of Bloodless Blood Tests is based on GPx founders’ unique backgrounds in Cardiac Rhythm Management, Heart Failure, Digital Health, and Point-of-Care Diagnostics, which allows them to blend digital and biological biomarkers in an unprecedented manner to predict disease progression. “Enrolling the first patient in this heart failure study is a significant milestone in our mission to improve the care and quality of life of heart failure patients and further validates our vision for creating a new category of clinically validated digital biomarkers called Bloodless Blood Tests,” said Javier Echenique, Co-Founder and CEO of General Prognostics.  
 
About Heart Failure
Heart failure (HF) affects around 6 million people in the U.S. and over 26 million people worldwide. HF patients constitute 30% of global hospital readmissions, totaling $6.6B in cost in 2019, and forecasted to triple by 2025. Despite doctor visits every few months, less than 1% of HF patients are on optimal medical therapy. Significant changes in patients’ conditions often require therapy updates to maintain stability, but usually go unnoticed due to the difficulty of remote monitoring. Current monitoring options are ineffective due to inaccuracy, user burden, or cost. As a result, this limited access to patient data causes patients that could otherwise be stabilized via updates to their therapy, to end up readmitted to the hospital. 
 
About General Prognostics 
General Prognostics is revolutionizing remote chronic disease management with the world’s first Bloodless Blood Tests. Headquartered in Boston, MA, GPx is a development-stage company and dedicated to transforming the standard of care of cardiorenal diseases and enabling patients to better understand their condition, much like the continuous glucose monitor has transformed diabetes care. GPx was also in the Sony Startup Accelerator Program Europe 2021 batch and winner of the Boston Scientific Connected Patient Challenge VI. 

Contact Information

Sean Matsuoka

Co-Founder

General Prognostics (GPx)

contact@generalprognostics.com